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Severe hyperhidrosis can cause extreme embarrassment that may lead to social and professional isolation. Therapeutic
strategies to hyperhidrosis should employ the least invasive treatment that provides effective symptom control. The treatment
options available for control of hyperhidrosis, non-surgical or surgical, differ in their invasiveness and efficacy. Mechanisms
of action of antiperspirants, iontophoresis, cholinergic inhibitor drugs, botulinum toxin, and surgical sympathectomy are
reviewed.
There is little published evidence in the form of comparative randomised trials to support the use of one treatment over
another. However, authors have tended to recommend those therapies that are available to their speciality. Specific therapies
should be tailored to the patient’s symptoms to gain maximum symptomatic improvement with minimum invasiveness and
side-effects. To achieve this, the full range of treatment options should be available to, or accessible by the consulting doctor in
order for the patient to have a meaningful choice.
Key Words: Hyperhidrosis; Antiperspirants; Iontophoresis; Anticholinergic drugs; Botulinum toxin; Surgical sympath-
ectomy.
Introduction
There are now a number of treatment options available
for the control of hyperhidrosis. These differing
therapies vary in their invasiveness, efficacy and
side-effect profile. Although authors often seek to
highlight the benefits of one treatment over another,
specific therapies can now be tailored to a patient’s
individual requirement, to gain maximum sympto-
matic improvement with minimum invasiveness and
side-effects. This review aims to provide an overview
of treatments in current use together with their
proposed mechanisms of action, and to provide
support for a symptom-targeted approach to the
management of hyperhidrosis.
Physiological sweating is essential for regulation of
body temperature. With increasing body temperature
thermoreceptors in the hypothalamus detect
elevations in blood temperature and trigger increased
sympathetic activity to the body’s 2–5 million sweat
glands, to increase sweat production and effect cooling
of the body. The symptom of hyperhidrosis can be
defined as sweating in excess of the body’s homeostatic
requirements. Mild hyperhidrosis is common and
merges with sweating in the normal population. In its
severe form, hyperhidrosis is a distressing symptom that
affects 1% of the population. Hyperhidrosis is usually
described as primary when it occurs in isolation (the
more common form) or secondary when it occurs
because of another disease process or treatment.
Secondary hyperhidrosis tends to be a more
generalised symptom with sweating involving most
body parts. Secondary hyperhidrosis is typically
associated with endocrine diseases (including
hyperthyroidism, diabetes, obesity and menopausal
change) but also occurs with malignancy and psychia-
tric disorders.1 – 6 Secondary hyperhidrosis can also be
iatrogrenic. Nerve injury can cause localised sweating
in the area surrounding its cutaneous distribution.7
Prescribed medication can also cause generalised
sweating. Many drugs have sweating as a side-effect
and gonadorelin analogues and tricyclic antidepress-
ants are typical of these.8,9 Treatments for secondary
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hyperhidrosis should be directed at the underlying
causative process and will not be considered further in
this review.
The cause of primary hyperhidrosis is unknown. It
typically presents in childhood or adolescence, and
there appears to a genetic basis to the observed
familial tendency to increased sweating.10 The symp-
tom of primary hyperhidrosis affects the palms,
axillae, plantar surfaces, face and neck, and torso in
decreasing frequency but also in different combi-
nations. This sweating may be episodic, continuous
or seasonal and may be exacerbated by nervousness or
anxiety and blushing. Severe hyperhidrosis can cause
extreme embarrassment that may lead to social and
professional isolation. These symptoms may last for
life. Therapeutic strategies to hyperhidrosis should
employ the simplest treatment that provide effective
symptom control.
Methods
A literature search was performed on the medline
database using the terms hyperhidrosis, sweating,
sympathectomy, botulinum toxin, antiperspirants,
iontophoresis and anticholinergic drugs. All relevant
abstracts were reviewed and relevant papers were
further assessed. Further articles were extracted by
cross-referencing and illustrative papers were used in
this review.
Therapeutic approaches for hyperhidrosis
A number of treatments are now available with which
to target primary hyperhidrosis. Most treatments are
directed locally, reflecting the local pattern of symp-
tom presentation. Local treatments may be classified
as non-surgical or surgical. Systemic treatments tend
to be reserved for patients with more generalised
symptoms. Specific treatments for hyperhidrosis tar-
get specific parts of the neuro-endocrine pathway at:
the thoracic sympathetic chain, axonal conduction, the
axon-sweat gland synapse, the glandular production
of sweat and the passage of sweat to the skin surface.
Following this pathway in reverse: surgical skin
excision works by removing the affected sweat glands,
antiperspirants occlude sweat pores to prevent sweat
reaching the skin surface, iontophoresis prevents
sweat production within the gland, cholinergic inhibi-
tor drugs block neurotransmitter receptor sites on the
sweat gland, botulinum toxin disables neurotrans-
mission to prevent distal axonal neurotransmitter
release, and surgical sympathectomy disconnects the
peripheral sympathetic nerves from the sympathetic
chain. These treatments are described below.
Non-surgical therapies
Antiperspirants
Aluminium based compounds have been long used in
hyperhidrosis and act by causing sweat to thicken and
clump.11 These clumps plug the surface pores and
prevent ‘new sweat’ from reaching the skin surface
thereby preventing hyperhidrosis. The sweat plugs
eventually dissolve and become ineffective, thus neces-
sitating regular reapplications of treatment. Antiper-
spirants are mostly used for axillary symptoms. Much of
the population use mild aluminium-based antiperspir-
ants in sprays and roll-on applications to inhibit normal
sweating. In clinical hyperhidrosis, 20–25% aluminium
chloride in 70% alcohol is a popular first line treatment
especially for palms and axillae.12,13 Formulations such
as Driclorw (Steifel Laboratories, High Wycombe UK)
are usually applied as a roll-on at night, 2–3 times
weekly, and then washed off in the mornings. This
usually provides effective control for mild to moderate
hyperhidrosis. However, its continued use is often
limited by rashes, stinging sensations and irritation.14
Driclor should not, therefore, be used on recently
shaved, irritated or broken skin.
Iontophoresis
Iontophoresis treatment involves immersion of the
sweating area in a solution, and the use of low
intensity electrical current from a D/C generator to
drive charged ions in the skin. Although the exact
mechanism of action at the sweat gland is unknown,
the ionic changes temporarily disrupt the function of
sweat glands in the treated area.15 Multiple weekly
sessions can give prolonged dryness of the treated
surfaces, particularly on the volar surfaces that best
lend themselves to this treatment.16,17 Iontophoresis
devices such as Idrostarw (STD Pharmaceuticals,
Hereford, UK) are commercially available and can be
purchased for home use. However, clinical experience
is that many patients find iontophoresis time-consum-
ing and inefficient. Further, its application to body
parts other than the volar surfaces presents practical
difficulties that the companies have tried to address.
Iontophoresis appears to be safe in normal patients
and its only common side-effect is mild irritation that
responds well to hydrocortisone cream. Because of the
electric currents involved iontophoresis should not be
used in pregnancy or in the presence of cardiac
pacemakers and metal implants.
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Cholinergic inhibitor (anticholinergic) therapy
Anticholinergic drugs may be administered orally
and, among other effects, inhibit acetylcholine receptor
sites on the sweat gland to stop sweat production.18
Anticholinergics are the only systemic treatment in
regular use and should be considered in patients with
more generalised sweating. However, the ubiquitous
nature of acetylcholine receptors in the body leads to
widespread anticholinergic side-effects that limit
patient compliance with these drugs. The most
effective anticholinergic drug, glycopyrrolate (Robi-
nulw and Robinulw Forte, Mikart, Inc., Pharmaceutical
Manufacturers, Atlanta, GA) has mild side-effects and
is generally well tolerated. Robinulw is not currently
available through NHS prescription in the UK but can
be obtained by private prescription and imported from
USA.19 Topical glycopyrrolate has also been used in
the treatment of localised secondary gustatory sweat-
ing.20
Botulinum A toxin-haemagglutin complex
Botulinum toxin, administered by multiple local
intradermal injection, prevents acetylcholine release
at the axonal synapse with the sweat gland to stop
sweating. It is an effective outpatient treatment for
localised hyperhidrosis and has stimulated much
recent interest.21 – 23 Although there are no trials
comparing this with surgery, botulinum toxin is
currently used for the first line treatment of axillary
hyperhidrosis in secondary care. Following intrader-
mal injection the treated skin remains dry for a period
of 4–14 months in a dose dependent action and
treatments can be repeated when required.24,25 How-
ever, antibody formation to the toxin can limit the long
term efficacy of botulinum toxin treatment. Botulinum
toxin-induced local muscle group paralysis presents a
problem that limits its usage in the hand although
successful hand treatments continue to be
reported.26 – 28 Rash formation, transient burning sen-
sation and compensatory hyperhidrosis in the sur-
rounding skin are rare complications that do not limit
botulinum toxin use in the axilla.
Surgical therapies
Excision of affected skin
Local skin excision was formerly used in axillary
hyperhidrosis. This radical approach is limited by
poor cosmesis, abscess and sinus formation, and
hypertrophic and constrictive scarring and is now
seldom used. Subcutaneous removal of sweat glands
may offer a more acceptable direct approach to sweat
gland removal.29 – 31
Open surgical sympathectomy
Open sympathectomy interrupts the sympathetic
chain to abolish sweating. Although this is potentially
achievable for sweating at all body sites, only the chain
for the upper body is easily accessible without the
need for extensive dissection. Interruption of the
upper thoracic sympathetic chain via an open cervical
or thoracic approach effectively treats palmar, axillary
and facial hyperhidrosis in the majority of
patients.32 – 34 Conventional open sympathectomy is
now rarely used due to the extensive and traumatic
dissection required to gain access to the sympathetic
chain, with its increased rates of unacceptable side-
effects.
Transthoracic endoscopic sympathectomy (TES)
TES has gained in popularity over the last decade as
the surgical treatment of choice for palmar and facial
hyperhidrosis.35 – 38 This minimally-invasive pro-
cedure, via one or two chest portals per hemithorax,
is safe in experienced hands and is associated with
negligible scarring.39,40 TES is usually performed
through 10 and 5 mm portals, however, smaller portals
of 2–3 mm have been tried with variable success.41,42
Although not in routine use, changes in skin tempera-
ture can be used for intraoperative confirmation of
effective sympathectomy.43,44 Satisfactory control of
sweating is up to 95%, 85% and 75% of patients for
palmar, facial and axillary symptoms, respectively.
TES is undoubtedly effective for upper body hyperhi-
drosis, however the supportive published evidence is
mainly from quality of life studies and series from
single centres rather than randomised trials.45 – 47
Curiously, successful upper limb treatment may also
be associated with improved pedal symptoms.48
Controversies exist even when transthoracic sym-
pathectomy has been chosen as the treatment of
choice. Here, the use of double lumen versus single
lumen endotracheal tubes continues to be debated.
Current technical controversies include the use of
carbon dioxide insufflation versus no insufflation,
diathermy coagulation of the sympathetic chain versus
scissor dissection/excision, and sympathetic chain
transection versus surgical clip application. Each
technique has advocates, however, these views are
not supported by comparative randomised controlled
trials.
Chest scarring from previous surgery or pulmonary
disease are contraindications to TES, and the pro-
cedure may be attended by a number of complications.
Compensatory hyperhidrosis is the commonest com-
plication of TES and affects 50–70% of patients.49
Affected patients present with increased sweating of
the trunk and groins that is usually mild and
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acceptable to most patients. The influence of the extent
of surgical sympathectomy on this symptom remains
uncertain.50 In up to 11% of patients the severity of
compensatory hyperhidrosis may lead the patient to
regret the TES procedure.51,52 Pneumothorax, hae-
mothorax, Horner’s syndrome, pleuritic chest pain,
intercosto-brachial neuralgia and recurrence of hyper-
hidrosis are other complications affecting a minority of
patients in reports.53 – 55 Cardiovascular side-effects
may also occur.56 The apparent rarity of these
complications may represent a reporting bias in the
medical literature as some patient groups do not share
the surgeons’ optimistic view on side-effects. A brief
review of patient reports on the internet shows that
patient groups do not regard these side-effects as rare
or untroubling. Patients also report many other side-
effects that rarely appear in the medical literature
(http://home.swipnet.se/sympatiska/).
Other therapies
Many unproven therapies have been tried for hyper-
hidrosis. Dusting powders are unhelpful as profuse
sweating washes the powder away. Other alternative
therapies including homoeopathy, massage, acupunc-
ture, hypnosis and phytotherapeutic drugs have not
been found to be helpful. Hypnosis, psychotherapy
and psychopharmacologic therapies have not cured
hyperhidrosis but may help some patients to accept
living with their symptom.
Conclusion
Many controversies exist in the selection of treatment
for patients with primary hyperhidrosis. There are no
good randomised controlled trials comparing one
treatment modality for hyperhidrosis with another.
For example, trials of iontophoresis have tended to
compare treatment with placebo rather than say
botulinum toxin or surgery. Similarly botulinum
toxin is usually compared with saline or dosage
studies. Thus the emergence of botulinum toxin as
the first choice treatment for axillary hyperhidrosis has
occurred without any trials with the previous best
treatment. Like laparoscopic versus open cholecystet-
omy a decade ago, it may now be too late to perform a
trial of say botulinum toxin injections versus surgical
sympathectomy for axillary hyperhidrosis, because of
the marked difference in the degree of invasiveness
and patient preference between the two treatments.
This present state exists because of the lack of
published evidence in the form of comparative
randomised trials that support the use of one treat-
ment of hyperhidrosis over another. Despite this,
review authors have tended to recommend specific
therapies based on speciality familiarity rather than
objective comparative evidence. Papers from derma-
tology journals tend to favour non-surgical
approaches57 whilst surgical papers have had a bias
to operations.58 Neither approach is useful in isolation,
as some patients from each clinic will be denied
treatments that may be more appropriate for their
specific symptoms. Review papers from dermatology
clinics present an overly optimistic view of dermato-
logical treatments (antiperspirants, iontophoresis,
botulinum toxin) with underplay of side-effects, and
a pessimistic view of surgical procedures. In palmar
hyperhidrosis for example, Togel’s review strongly
favours first line use of tap water iontophoresis, with
botulinum toxin (with its known small muscle effects)
as a second line treatment. Transthoracic sympathec-
tomy with its 95% success rate, likelihood of perma-
nent cure and strong patient acceptability is not
recommended. Equally controversial is the rec-
ommendation of antiperspirants (based on a 90%
success for desired effects) rather than botulinum toxin
injections, for first line treatment of axillary hyperhi-
drosis.57 Practical experience suggests that many
patients cannot tolerate the local irritation of strong
antiperspirants and discontinue their use within a
short time.
This present review attempts to depart from these
prejudiced approaches by describing all established
treatments of proven efficacy, together with their
limitations. This author, because of lack of compara-
tive evidence, makes no strong argument in favour of
any one treatment over another in terms of efficacy.
The modern treatment for hyperhidrosis should be
tailored to the individual’s symptoms and major sites
of body involvement. To achieve this, the full range of
treatment options should be available to or accessible
by the consulting doctor in order for the patient to
have a meaningful choice. The ultimate decision for
treatment, especially when surgery is considered,
should be reached with each patient in the light of
the impact of the symptoms on their quality of life.
Decisions should be made only after a good under-
standing of the risks as well as the benefits has been
gained. Treatment side-effects tend to be under
reported and clinicians should strive for careful
follow-up, with documentation of all side-effects.
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